Navigation Links
Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
Date:10/27/2009

Phase II study results in type 2 diabetes patients with nonalcoholic fatty liver disease, supports INT-747's potential as a novel therapeutic across a range of chronic liver diseases. We intend to present the complete data set from the study at an appropriate scientific meeting in 2010."

Intercept's Chief Medical Officer, David Shapiro, MD, commented, "This study involved more than 30 centers in eight countries and has given us a better understanding of the needs of PBC patients, as well as a good working relationship with the hepatologists looking after them across North America and Europe. With this PBC network in place, we are well positioned to conduct a Phase III program. We intend to request an End of Phase II Meeting with FDA to review the results and plans for a Phase III program."

About INT-747 (first-in-class FXR agonist)

INT-747 is a potent, first-in-class farnesoid X receptor (FXR) agonist derived from the primary human bile acid chenodeoxycholic acid (CDCA), the natural endogenous FXR agonist. INT-747 is formulated as an orally bioavailable drug given once daily. Bile acid signaling through FXR has been shown to regulate the regenerative properties of the liver and, in numerous animal models of liver disease, INT-747 treatment prevents, and even reverses, liver damage caused by progressive fibrosis (scarring). FXR is also expressed in the intestine and kidney and INT-747 exhibits similar protective antifibrotic effects in models of inflammatory bowel disease and diabetic nephropathy.

About Intercept Pharmaceuticals

Intercept is a clinical stage biopharmaceutical company focused on discovering and developing small molecule drugs for the treatment of chronic fibrotic and metabolic diseases. The company's most advanced programs are focused on the development of modified bile acids that are selective for FXR, a nuclear receptor, and TGR5, a G protein-coupled receptor. Intercept's le
'/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
2. Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
3. BioMarin Acquires Huxley Pharmaceuticals, Inc.
4. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
5. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
7. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
8. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
9. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
10. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
11. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... According to a new market research report ... Display, & Microprocessor/MCU), by Application (Imaging, Medical Therapeutics, Diagnosis, ... Global Forecast to 2020", published by MarketsandMarkets, the total ... $56.50 Billion by 2020, growing at a CAGR of ... market data Tables and 71 Figures spread through 312 ...
(Date:9/17/2014)... , Sept. 17, 2014 An analysis ... regarding patients taking Sovaldi® (sofosbuvir), a new and expensive ... shows that over the last several months (May through ... downward trend in Sovaldi utilization. This suggests another surge ... new therapeutic regimens of similar efficacy and shorter duration ...
(Date:9/17/2014)... MORRISTOWN, N.J. , Sept. 17, 2014 /PRNewswire/ ... LLP (MDM&C), today announced that it will serve ... the Benefits and Avoiding the Risks of Healthcare ... 2014 that will examine delivery systems, reimbursement, compliance ... Affordable Care Act. Logo -  ...
Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2
... Conn., Sept 18 Further results from the initial clinical trial ... for varicose veins, will be delivered on Friday, September 25, at ... The device combines mechanical and chemical modalities to accomplish vein treatment ... Steve Elias MD FACS FACPh, Associate Professor of Surgery at Mount ...
... NEWNAN, Ga., Sept. 16 CeloNova BioSciences, Inc. today announced ... the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) conference ... treating liver cancer. Professor Orsi and his colleagues at the ... technique to cut off the blood supply inside liver tumors ...
Cached Medicine Technology:ClariVein(TM) Catheter for Varicose Veins: Further Clinical Trial Results to Be Presented 2New Micro-Bland Embolization Technique with Embozene(TM) Microspheres to Be Presented at the International Medical Conference in Lisbon, Portugal 2
(Date:9/17/2014)... Recently, UWDress.com, an innovative company that provides many kinds ... released its 2014 empire waist evening dress ... big sale for these new and beautiful products. All ... from 15 to 65 percent off. , It ... to wear materials. Its elegant items include gold empire ...
(Date:9/17/2014)... September 18, 2014 IntimateRider, an inventor ... adults , has announced that it has entered into ... & Mobility LLC. A primary reason for the deal ... distribution reach is global. About its sales potential, representatives ... to provide you with the latest products on the ...
(Date:9/17/2014)... September 18, 2014 iFitDress.com, a renowned wedding ... of petite evening dresses . All these outfits are ... and discounted shipping costs. , ā€œiFitDress.com is a professional ... gowns. We are now busy selling our new collection of ... place an order above $800 can get free shipping. All ...
(Date:9/17/2014)... September 18, 2014 The National Resident ... Match , a comprehensive analysis of the relationship between ... preferred specialty. The new edition is based on ... specialty for U.S. allopathic medical school senior students and ... be able to provide this new edition of Charting ...
(Date:9/17/2014)... Columbus, Ohio (PRWEB) September 18, 2014 ... cycle management services nationwide, announces today that they ... Fort Wayne Radiology (FWRadiology) in Fort Wayne, Indiana. ... range of billing services encompassing their proprietary suite ... Technology (EBT). EBT improves radiology billing and ...
Breaking Medicine News(10 mins):Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 2Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 3Health News:Elegant Petite Evening Dresses Introduced By Renowned Supplier iFitDress.com 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 3Health News:ADVOCATE Wins Radiology Billing Agreements with Fort Wayne Radiology 2Health News:ADVOCATE Wins Radiology Billing Agreements with Fort Wayne Radiology 3
... ... 10 NBTY, Inc. (NYSE: NTY ) ( www.NBTY.com ), a ... President and Chief Financial Officer will be interviewed live on FOXBusiness.com LIVE on ... www.foxbusiness.com/live on Friday, December 11, 2009 between 12 and ...
... , ... know much about depression , but are highly aware of ... by the National Alliance on Mental Illness (NAMI). ... Web site that includes resources for people of diverse communities. , ...
... that tuberculosis bacteria use to coerce disease-fighting cells to ... line the airways and other surfaces to protect and ... into helping create tubercles: the small, rounded masses characteristic ... their numbers and spread to other locations. ...
... ... Laser-type device to be coupled with Stem Cell Therapy in Novel ... San Diego (PRWEB) December 10, 2009 -- Entest Biomedical Inc. ... with Advanced Light Devices to develop a proprietary laser system. It is anticipated this investigational medical device will ...
... , New report notes that ... could decline by 36 percent , Oak Brook, Ill., ... (ASGE) lauds the recent news of the decline in U.S. colorectal ... that from 1975 to 2000, incidence rates dropped 22 percent and ...
... alcoholic beverages (at least three to four drinks per week, ... 30 percent increased risk of breast cancer recurrence, according to ... be most susceptible to the effects of alcohol on recurrence, ... this study will be presented December 9-13 at the Cancer ...
Cached Medicine News:Health News:NBTY to be Featured on the FOX Business Program FOXBusiness.com LIVE 2Health News:Depression Survey: Implications for Diverse Communities 2Health News:Mechanism discovered by which body's cells encourage tuberculosis infection 2Health News:Mechanism discovered by which body's cells encourage tuberculosis infection 3Health News:Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment 2Health News:Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment 3Health News:ASGE Lauds Drop in Colorectal Cancer Deaths 2Health News:ASGE Lauds Drop in Colorectal Cancer Deaths 3Health News:ASGE Lauds Drop in Colorectal Cancer Deaths 4Health News:Alcohol consumption may increase breast cancer recurrence risk 2
... The Venus-i Laser System is a ... laser system with applications in dermatology, cosmetic ... ophthalmology. An ideal laser for skin resurfacing, ... most powerful, Erbium:YAG lasers on the market. ...
... Laser System is a new, portable, light ... applications in dermatology, cosmetic and plastic surgery, ... laser for skin resurfacing, it is the ... lasers on the market. It provides an ...
... biolitecs Ceralas D 980 nm diode ... clean, bloodless field for most surgical procedures. ... D cuts optically without collateral tissue ... laser coagulates blood instantly and seals small ...
... The APTIMA COMBO 2 Assay is ... that uses target capture for in vitro ... CT and GC. The assay uses a ... capture (TC), Transcription-Mediated Amplification (TMA) and Dual ...
Medicine Products: